A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial compares three chemotherapy regimens consisting of bendamustine,
rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating
patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as
bendamustine and cytarabine, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer
cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. This study is being done to find out if one the drug
combinations of bendamustine, rituximab, high dose cytarabine, and acalabrutinib is better or
worse than the usual approach for mantle cell lymphoma.